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Abstract
This phase II study evaluated the toxicity and efﬁcacy of docetaxel and carboplatin as salvage therapy in 36
patients with relapsed, platinum-sensitive ovarian cancer. The most common and signiﬁcant toxicity was
hematologic. The best response was seen in patients with ‡ 1-year remission before relapse.
Background: The optimal therapy to treat relapsed, platinum-sensitive ovarian cancer remains elusive. Because most
patients receive initial therapy with paclitaxel and platinum, there is a lack of cross-reaction of docetaxel and paclitaxel
and retreatment with platinum is standard of care; we evaluated the toxicity and efﬁcacy of docetaxel and carboplatin
as salvage therapy for relapsed, platinum-sensitive ovarian cancer. Materials and Methods: This phase II study
treated the ﬁrst-relapsed, platinum-sensitive, stage III/IV ovarian cancer patients with docetaxel 80 mg/m2 intravenous
(IV) over 60 minutes followed by carboplatin area under the curve 6 IV over 30 minutes every 21 days, for 6 cycles. End
points were toxicity, response rates, relapse rates, event-free survival, and survival rates. Results: Thirty-six patients
were enrolled and 35 were evaluable. Twenty-three percent of patients were age  70 years. A total of 170 cycles of
therapy were given. Ten patients required dose reduction. Thirty-eight percent had a delay in starting subsequent
planned cycles. Most delays were due to hematologic recovery. Hematologic toxicity was most common and sig-
niﬁcant; 77% grade 4 neutropenia. One patient died from typhilitis. Total complete remission (38%) and partial
remission (27%) rate was 65%. Median time to progression was 261 days (60-717). Five (14%) patients remain alive
without ovarian cancer, with median follow-up of 5.1 years. Patients who entered the study with  12-month duration
of initial remission had best response. Conclusion: The combination of docetaxel and carboplatin has toxicity,
especially hematologic, and requires growth factor support and close monitoring for infections. Its role for treating
ovarian cancer patients was better in patients in whom initial response to therapy was  12 months.
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In spite of recent advances in the treatment of advanced ovarian
cancer, most patients still succumb to the disease. The optimal
therapy to treat relapse disease remains elusive. For patients with
platinum-sensitive, relapsed disease, the standard of care is to retreat
with platinum-based therapy. Because there is a lack of cross-
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http://dx.doi.org/10.1016/j.cogc.2014.12.005activity in ovarian cancer,2,3 it seemed reasonable to study a com-
bination of docetaxel and carboplatin as salvage therapy.
This study investigated a regimen similar to that used by
Belani in a lung cancer study.4 It should be noted that while
this study was conducted, both ICON4/AGO Ovarian 2.2 trial
and AGO OVAR 2/5 trial published the results of their
clinical trials that conﬁrm the advantage of doublet platinum/
carboplatinebased combination chemotherapy over monotherapy
therapy.5,6
Patients and Methods
Thirty-six patients with the ﬁrst-relapsed, platinum-sensitive
stage III/IV advanced ovarian cancer were enrolled to be treated
with docetaxel and carboplatin. One patient was not treated on
study. Patients were eligible for this clinical trial if they had relapsed
> 6 months from completion of platinum therapy. Patients couldClinical Ovarian and Other Gynecologic Cancer December 2014 - 13
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14 -be treated on the basis of an elevated serum CA 125 ( 100,
conﬁrmed by 2 blood tests at least 1 week apart) and/or evidence of
measurable disease by physical examination or radiographic
(computed tomography [CT]) evaluation. Patients needed to have a
platelet count  100,000 cells/mL, absolute neutrophil count
 1500 cells/mL, Karnofsky score  60, creatinine clearance > 50
cc/minute, and serum creatinine  2.0 mg/dL, total bilirubin
< upper limit normal (ULN), and alanine aminotransferase and
aspartate aminotransferase  5  ULN with normal alkaline phos-
phatase. Patients were excluded from therapy if HIV seropositive, had
poorly controlled arrhythmias, left ventricle ejection fraction  50%,
uncontrolled coronary artery disease or myocardial infarction within
the last year, or peripheral neuropathy > grade 2.
Signed consent was obtained from all patients treated through
Puget Sound Oncology Consortium. Protocol was approved by
Fred Hutchinson Cancer Research Center (FHCRC) Institutional
Review Board (IRB) and by the IRB of the hospital where therapy
was administered.
Deﬁnitions
Patients were restaged nonsurgically before administration of
therapy. Complete baseline staging included chest x-ray, CT
abdomen/pelvis, physical examination, and CA 125 blood test. All
patients were restaged after third and sixth cycles of therapy.
Thereafter, they had CA 125 tested every 3 months for the ﬁrst 2
years, then every 6 months until disease progression or death, and
they had CTs every 6 months for the ﬁrst 2 years and then yearly
until disease progression or death.
Duration of response was calculated from beginning of therapy.
Responses were deﬁned as complete remission (CR) if there was a
disappearance of all gross evidence of disease and normalizations of
CA 125 for at least 4 weeks in patients with measurable disease or
normalization in patients with CA 125 elevated alone as evidence of
disease for 4 weeks. Partial remission (PR) was deﬁned as  50%
reduction in product obtained after measurement of each lesion for
at least 4 weeks or  50% decrease in CA 125 in patients with only
elevated CA 125 for 4 weeks. Progression of disease was deﬁned
as  50% increase in product of any previously documented lesion,
appearance of new lesions, or  50% increase in CA 125 within 8
weeks of entry into study. Stable disease was deﬁned as any con-
dition that did not meet the previously deﬁned criteria.
Treatment Schedule
Docetaxel 80 mg/m2 by 1-hour infusion intravenous (IV) fol-
lowed by carboplatin area under the curve 6 IV infusion over 30
minutes was administered every 21 days, with plan to give at least
6 cycles. Premedication with dexamethasone 8 mg twice daily for 3
days was begun 24 hours before infusion of docetaxel. Carboplatin
dose was calculated based on 6 (24 hour measured creatinine urine
clearance þ 25). Dose of carboplatin was recalculated for each cycle.
Antiemetics, including 5-HT antagonists, were recommended.
Initially, granulocyte -colony stimulating factor support was allowed
if patients developed febrile neutropenia, sepsis that required IV
antibiotics, ANCs fell 1000 to 1500 after 2 to 3 weeks’ delay, or
ANC  500 for 7 consecutive days. When degree of neutropenia
was seen in the ﬁrst group of patients, all patients received Neulasta
(pegﬁlgrastim) 6 mg with each cycle of chemotherapy.Clinical Ovarian and Other Gynecologic Cancer December 2014There were dose reductions in docetaxel and carboplatin for delay
of initiation of therapy because of decreased platelet and neutrophil
count, neurologic toxicity > grade 2,  50% in serum creatinine,
and increased serum transaminases. The lowest dose for carboplatin
was area under the curve 4 and for docetaxel was 60 mg/m2.
Patients were withdrawn from treatment on study if
they developed  grade 4 neurologic toxicity,  grade 3
nonhematologic/non-neurologic (except increased transaminases
and fatigue) or if there was a delay > 3 weeks from receiving the
next cycle for any major toxicity. Therapy could not be given until
platelet count recovered to  100,000 cells/mL and neutrophil
count  1500 cells/mL. Regimen-related toxicity grading was per
National Institutes of Health/National Cancer Institute common
toxicity criteria, 1998 version.
Statistics
Actuarial probabilities of survival and event-free survival (EFS)
were computed according to Kaplan and Meier.7 Survival was
calculated from start of the ﬁrst cycle of therapy until death or date
of last contact. The end point for EFS was relapse, second cancer, or
death. Patients who never achieved a CR, PR, or stable were
considered to have relapsed on day 1 after the ﬁrst cycle of therapy.
The median follow-up of all patients was 1862 days.
Results
Patient Characteristics
No patients had received docetaxel before enrollment to the
study. All patients had been previously treated with paclitaxel and
carboplatin or carboplatin alone. Five patients had been also treated
previously with gematabine, 1 with topotecan and 1 with cyclo-
phosphamide. One patient received intraperitoneal chemotherapy.
Twenty-three percent of patients were aged  70 years. Twenty-two
patients had soft tissue involvement, including lung, liver, spleen,
kidney, or lymph node involvement above or below diaphragm by
CT criteria (Table 1).
Delivery of Scheduled Therapy
A total of 170 cycles of therapy were given. One patient was
enrolled, but referring oncologist never started study therapy;
thus, 35 patients are evaluable. Twenty-six patients (74%)
completed planned 6 cycles of therapy. One patient died of
regimen-related toxicity from typhilitis complications with her
ﬁrst cycle of therapy. One had therapy discontinued because of
dose-limiting toxicity; although, of note, the treating physician
retreated with study regimen when patient recovered from acute
toxicity. Seven patients had progression of disease while on
therapy. Ten of 35 evaluable patients (29%) required dose
reduction in docetaxel or carboplatin. Thirteen of 35 evaluable
patients (38%) had a delay in starting subsequent cycle beyond
3 weeks. Most of these delays were caused by hematologic
recovery.
Toxicity
Fourteen patients were hospitalized during therapy. Nine patients
received erythropoietin, 1 patient received platelet transfusions, and
6 patients received red blood cell transfusions. The incidence of
grades 2 to 5 toxicity is listed in Table 2.
Table 1 Patient Characteristics (n [ 35)
Characteristic Number Percentage (%)
At Initial Diagnosis
Stage IIIB/IIIC 1/24 71
Stage IV 6 17
Histology At Initial Diagnosis
Serous 22 63
Endometrioid 2 6
Mixed 4 11
Undifferentiated 7 20
Poorly differentiated grade 27 77
Prior Therapy
Chemotherapy 1 regimen 28 80
Chemotherapy 2 regimens 7 20
Immunotherapy 3 9
Endocure therapy 3 9
Median Time From Initial Diagnosis
to Relapse
26 months;
range, 11-61
Median Time From the Last Therapy
to Relapse
21 months;
range, 6.1-52
Platinum-Free Interval (mo)
6-11 12 34
12 23 66
Median Age at Start of Study
Therapy (years)
59 years;
range, 31-80
<60 19 54
60-69 8 23
70 8 23
At Entry to Study
Elevated CA 125 alone (100) 8 23
Measurable disease by computed
tomography or physical examination
27 77
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Twenty-seven of 35 patients (77%) developed grade 4 neutropenia
and 4 of 35 (11%) grade 3 neuropenia. Twenty of 35 patients (57%)
had grade 2/3 anemia. Four of 35 patients (11%) had grade 2/3Table 2 Incidences of Noninfectious Toxicity
Category Grade 2 Grade 3 Grade 4 Grade 5
GI 15 1 0 0
Metabolic 4 1 0 0
Pulmonary 4 0 0 0
Circulatory 6 0 0 0
Neurologic 4 0 0 0
Platelets 3 1 0 0
Hemoglobulin 15 5 0 0
Allergy 4 1 0 0
Orologic 1 0 0 0
Dermatology 8 0 0 0
Cardiac 0 0 0 0
Other 7 0 0 0
Neutrophils 1 4 27 0thrombocytopenia. Most common other toxicity was fatigue. Eleven
percent developed grade 2 neurologic toxicity. Forty-six percent
manifested grade 2/3 gastrointestinal complaints, including stomati-
tis, nausea, vomiting, and diarrhea. Nineteen of 35 patients (54%)
had grade 2/3 infection. See Table 3 for types of infections. One
patient died of infectious complications from typhilitis.
Response
The best response obtained was 13 of 35 evaluable patients
(38%) achieving CR and 9 patients of 34 (27%) achieving PR, for a
total of 65% CR or PR rate. The median time to disease progression
was 261 days (60 to 717 days). Twenty-nine patients have relapsed
and all have died of complications of disease progress. Thirty pa-
tients have died: 29 of progressive ovarian cancer, including 2 from
brain metastases, and 1 from treatment-related typhilitis. The
actuarial probabilities of survival and EFS for all patients were
delineated in Figures 1 and 2. Of note, 5 patients (14%) remain
alive without ovarian cancer, with median follow-up of 5.1 years. In
the patients who entered the study with < 12 months of duration of
remission, all patients have relapsed and died. Five of 23 patients
(22%) who entered the study with  12 months of duration of
initial remission remain alive and in remission.
Discussion
A regimen of docetaxel and carboplatin was administered to ﬁrst-
relapsed, platinum-sensitive, advanced ovarian cancer patients. A
dose schedule was adapted from the Belani phase I study developed
for lung cancer patients and used for its intensiveness and lack of
cross-reacting with the prior paclitaxel therapy.4 With this drug
schedule, the most common signiﬁcant toxicity was neutropenia,
with 77% of patients experiencing grade 4 neutropenia. We had one
infectious death, second to complication of typhilitis, after the ﬁrst
cycle of therapy. About 12% of patients developed grade 2 neuro-
logic toxicity, and 46% had grade 2/3 gastrointestinal complaints.
All patients who relapsed < 12 months from completion of initial
course of therapy have since relapsed and died. Twenty-two percent
of patients who relapsed  12 months from completion of initial
course of therapy remain alive and in CR, with a median of 5.1-year
follow-up.
Since we started our study, there have been other drug schedules
studied for combining docetaxel and carboplatin.8,9 Neutropenia
grade 3/4 was seen in 60% of the patients with a CR and PR rate of
72%. Twelve percent of patients had grade 3/4 diarrhea. Of note,Table 3 Infections
Types Number of Incidences
Fever received IV antibiotics 4
Fever with neutrophils 2
Neutropenic fever 4
Pilondial cyst 1
Sinusitis 2
Stomatitis (Herpes simplex) 1
Typhilitis 1
Upper respiratory tract infection 2
Urinary tract infection 3
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Figure 1 Progression-Free Survival
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16 -the patients who stayed in CR all had diffuse peritoneal carcinoses as
only site of recurrence.
Differences do exist between our study and the studies by
Strauss et al.8 and Pokrzywinski et al.9 Our study used a combi-
nation higher dose of docetaxel and carboplatin than Strauss et al.
and, as a result, saw more profound neutropenia. Our study gave a
higher dose of docetaxel totally and gave it only on day 1,
compared to Pokrzywinski et al. who gave a dose of docetaxel
30 mg/m2 on day 1 and day 8 of 3-week cycles. The patient
characteristics were also different. The median platinum-free interval
was 33.6 months in the study by Strauss et al. and 21 months in
ours. Twenty percent of our patients had 2 different initial induction
therapy regimens. Our patients appeared to have more extensive soft
tissue involvement by physical examination and CT changes as seen
in 27 patients (77%). The patients on the study by Strauss et al. hadFigure 2 Survival
Clinical Ovarian and Other Gynecologic Cancer December 2014diffuse peritoneal carcinoses as only site of CT reoccurrence.
Both the study by Strauss et al. and our study show less beneﬁt to
patients with a platinum-free interval < 12 months, and other
treatment or clinical trial options than this regimen may be more
appropriate for this group. In addition, Pokrzywinski et al. showed
signiﬁcant improvement in FACT-O-T01 (P ¼ .13) with sequential
single-agent docetaxel followed by carboplatin. However, they also
showed decreased PFS.
The treatment schedule of docetaxel and carboplatin in our study
has toxicity, especially hematologic, and the scheduled dose requires
growth factor support and close monitoring for infections. Whether
our schedule has a role in treating advanced ovarian cancer patients
depends on whether there are continued durable responses in the
patients to date doing well and whether it is reasonable for patients
with more advanced, bulking, relapsed disease to accept a higher risk
Leona A. Holmberg et alof toxicity for better chance for debulking therapy. Of note,
although relapse remains a problem in most patients, the question of
adding maintenance therapy with the newer biological modiﬁers
after adequate debulking remains to be explored.
Conclusion
Docetaxel and carboplatin can be used as salvage therapy to
treat the ﬁrst-relapsed, platinum-sensitive Stage III/IV advanced
ovarian cancer patients. Five patients (14%) remain alive
without ovarian cancer, with a median follow-up period of
5.1 years.
Clinical Practice Points
 Docetexal and carboplatin is an effective salvage therapy for
advanced-stage relapsed platinum-sensitive ovarian cancer
patients.
 The regimen has toxicity, especially hematologic, and requires
greater support and dose monitoring of patients.
 Patients who entered the study with  12 months duration of
initial remission were more likely to remain alive and in remis-
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